RVVTF

Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.